Ticagrelor: Difference between revisions

Revision as of 19:22, 28 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Synonyms / Brand Names: Brilinta

Overview

Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.^[1]^[2] The drug was approved by the US Food and Drug Administration on July 20, 2011.^[3]

Prescribing Information

Brilinta (ticagrelor) tablet

References

↑ "Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.
↑ European Public Assessment Report Possia
↑ "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes". FDA. 20 July 2011.

[EPAR_Brilique-1] "Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.

[2] European Public Assessment Report Possia

[3] "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes". FDA. 20 July 2011.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-{{Drugbox
-| Verifiedfields = changed
-| Watchedfields = changed
-| verifiedrevid = 443228756
-| IUPAC_name = (1''S'',2''S'',3''R'',5''S'')-3-[7-[(1''R'',2''S'')-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
-| image = Ticagrelor 01.png
-| width = 300
-| image2 = Ticagrelor 18.gif
-| width = 300
-<!--Clinical data-->
-| tradename = Brilinta, Brilique, Possia
-| MedlinePlus       = a611050
-| licence_EU = Brilique
-| licence_US = Ticagrelor
-| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
-| pregnancy_US = C
-| pregnancy_category =
-| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
-| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
-| legal_US = Rx-only
-| legal_status =
-| routes_of_administration = Oral
-<!--Pharmacokinetic data-->
-| bioavailability = 36%
-| protein_bound = >99.7%
-| metabolism = [[Hepatic]] ([[CYP3A4]])
-| elimination_half-life = 7 hrs (ticagrelor), 8.5 hrs ([[active metabolite]] AR-C124910XX)
-| excretion = [[Biliary]]
-<!--Identifiers-->
-| CAS_number_Ref = {{cascite|correct|??}}
-| CAS_number = 274693-27-5
-| ATC_prefix = B01
-| ATC_suffix = AC24
-| ATC_supplemental =
-| PubChem = 9871419
-| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| DrugBank =
-| UNII_Ref = {{fdacite|correct|FDA}}
-| UNII = GLH0314RVC
-| KEGG_Ref = {{keggcite|correct|kegg}}
-| KEGG = D09017
-| ChEMBL_Ref = {{ebicite|changed|EBI}}
-| ChEMBL = 398435
-<!--Chemical data-->
-| chemical_formula =
-| C=23 | H=28 | F=2 | N=6 | O=4 | S=1
-| molecular_weight = 522.567 g/mol
-| smiles = CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
-| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
-| StdInChI = 1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
-| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
-| StdInChIKey = OEKWJQXRCDYSHL-FNOIDJSQSA-N
-|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-| ChemSpiderID = 8047109
-|  InChI = 1/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
-|  InChIKey = OEKWJQXRCDYSHL-FNOIDJSQBW
-| synonyms = AZD-6140
-}}
 __NOEDITSECTION____NOTOC__
 {{CMG}} {{AE}}{{JH}}